6533b7ddfe1ef96bd12753b8
RESEARCH PRODUCT
Biomarkers in Community-Acquired Pneumonia (Cardiac and Non-Cardiac)
Irene AldásRosario MenéndezRaúl Méndezsubject
medicine.medical_specialtybusiness.industrycardiaccardiovascularlcsh:RClinical courseHost responsebiomarkerslcsh:MedicineGeneral MedicineDiseaseReviewmedicine.disease03 medical and health sciencesPneumonia0302 clinical medicine030228 respiratory systemCommunity-acquired pneumoniamedicineBiomarker (medicine)pneumonia030212 general & internal medicinebusinessIntensive care medicinedescription
Community-acquired pneumonia (CAP) remains the first cause of morbidity and mortality worldwide due to infection. Several aspects such as severity and host response are related to its clinical course and outcome. Beyond the acute implications that the infection provokes in the host, pneumonia also has long-term negative consequences. Among them, cardiovascular complications and mortality are the most outstanding. Therefore, an adequate recognition and stratification of the risk of complications and mortality is crucial. Many biomarkers have been studied for these reasons, considering that each biomarker mirrors a different aspect. Moreover, the clinical application of many of them is still being deliberated because of their limitations and the heterogeneity of the disease. In this review, we examine some of the most relevant biomarkers that we have classified as cardiac and non-cardiac. We discuss some classic biomarkers and others that are considered novel biomarkers, which are mainly involved in cardiovascular risk.
year | journal | country | edition | language |
---|---|---|---|---|
2020-02-01 | Journal of Clinical Medicine |